Entering text into the input field will update the search result below

Lannett inks deal for levothyroxine

  • Lannett (NYSE:LCI) has entered into a future exclusive supply and distribution agreement for Levothyroxine Sodium Tablets USP of Cediprof, Inc., a wholly owned subsidiary of Neolpharma Pharmaceutical Group.
  • Under the agreement, Lannett will commence U.S. distribution no later than August 1, 2022. The Company will make an upfront payment of $20M and will receive a portion of the net profits.
  • The term of the agreement is 10 years, which begins upon commencement of distribution. Other terms were not disclosed.
  • Shares are up 2% premarket.

Recommended For You

Related Stocks

SymbolLast Price% Chg
LCINQ--
Lannett Company, Inc.